Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437072 | 1.00 | NPC1 (0.43) | NPC1BRD4MAPK1MAPTTDP1 | |
| SCHEMBL28334988 | 0.82 | NPC1 (0.42) | NPC1BRD4MAPK1MAPTTDP1 | |
| SCHEMBL17258686 | 0.80 | MEN1 (0.44) | NPC1BRD4MAPK1MAPTTDP1 | |
| SCHEMBL29564439 | 0.80 | MEN1 (0.44) | NPC1BRD4MAPK1MAPTTDP1 | |
| SCHEMBL28334986 | 0.77 | GAA (0.42) | NPC1BRD4MAPK1MAPTTDP1 | |
| SCHEMBL18787256 | 0.75 | KDM1A (0.45) | NPC1BRD4MAPK1MAPTTDP1 | |
| SCHEMBL23663364 | 0.74 | FFAR1 (0.47) | NPC1BRD4MAPK1MAPTTDP1 | |
| SCHEMBL28332769 | 0.74 | KDM1A (0.44) | NPC1BRD4MAPK1MAPTTDP1 | |
| SCHEMBL29703994 | 0.73 | KDM1A (0.48) | NPC1MAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL18787264 | 0.73 | KDM1A (0.48) | NPC1MAPK1MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786517-B2 | Methods of treatment using a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3619208-B1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220306624-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | disclosed |
| US-11299492-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220008403-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-01-13 | — | — | US | disclosed |
| US-11160800-B2 | Methods of treatment using a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210130351-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-10913740-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200121669-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-04-23 | — | — | US | disclosed |
| US-10251874-B2 | Crystalline forms of a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-04-09 | — | — | US | disclosed |
| US-10183942-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180319796-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2018204236-A1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20180311223-A1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-01 | — | — | US | disclosed |
| US-20180311226-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-01 | — | — | US | disclosed |
| US-10100049-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3371186-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | Theravance Biopharma R&D IP, LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017079205-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913740-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
| US-11299492-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
| US-11786517-B2 | Methods of treatment using a JAK inhibitor compound | JAK1, JAK2, JAK3 | NPC1 1577/4885BRD4 28/4885MAPK1 146/4885 |
| US-20180311223-A1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | NPC1 3708/4885BRD4 1251/4885MAPK1 278/4885 |
| US-20220306624-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
| US-20210130351-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
| US-20220008403-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | NPC1 1577/4885BRD4 28/4885MAPK1 146/4885 |
| US-20200121669-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | NPC1 1577/4885BRD4 28/4885MAPK1 146/4885 |
| US-20180319796-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
| US-11160800-B2 | Methods of treatment using a JAK inhibitor compound | JAK1, JAK2, JAK3 | NPC1 1577/4885BRD4 28/4885MAPK1 146/4885 |
| US-10183942-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
| US-20180311226-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | NPC1 1577/4885BRD4 28/4885MAPK1 146/4885 |
| US-10251874-B2 | Crystalline forms of a JAK inhibitor compound | JAK1, JAK2, JAK3 | NPC1 3708/4885BRD4 1251/4885MAPK1 278/4885 |
| US-10100049-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | NPC1 2148/4885BRD4 488/4885MAPK1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.